Ovidiu Tatar
Jewish General Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ovidiu Tatar.
BMJ Open | 2017
Gilla K. Shapiro; Samara Perez; Anila Naz; Ovidiu Tatar; Juliet Guichon; Rhonda Amsel; Gregory D. Zimet; Zeev Rosberger
Introduction Human papillomavirus (HPV), a sexually transmitted infection, can cause anogenital warts and a number of cancers. To prevent morbidity and mortality, three vaccines have been licensed and are recommended by Canada’s National Advisory Committee on Immunisation (for girls since 2007 and boys since 2012). Nevertheless, HPV vaccine coverage in Canada remains suboptimal in many regions. This study will be the first to concurrently examine the correlates of HPV vaccine decision-making in parents of school-aged girls and boys and evaluate changes in parental knowledge, attitudes and behaviours over time. Methods and analysis Using a national, online survey utilising theoretically driven constructs and validated measures, this study will identify HPV vaccine coverage rates and correlates of vaccine decision-making in Canada at two time points (August–September 2016 and June–July 2017). 4606 participants will be recruited to participate in an online survey through a market research and polling firm using email invitations. Data cleaning methods will identify inattentive or unmotivated participants. Ethics and dissemination The study received research ethics board approval from the Research Review Office, Integrated Health and Social Services University Network for West-Central Montreal (CODIM-FLP-16–219). The study will adopt a multimodal approach to disseminate the study’s findings to researchers, clinicians, cancer and immunisation organisations and the public in Canada and internationally.
Preventive Medicine | 2018
Ovidiu Tatar; Erika L. Thompson; Anila Naz; Samara Perez; Gilla K. Shapiro; Kristina Wade; Gregory D. Zimet; Vladimir Gilca; Monika Janda; Jessica A. Kahn; Ellen M. Daley; Zeev Rosberger
Primary screening for cervical cancer is transitioning from the longstanding Pap smear towards implementation of an HPV-DNA test, which is more sensitive than Pap cytology in detecting high-risk lesions and offers greater protection against invasive cervical carcinomas. Based on these results, many countries are recommending and implementing HPV testing-based screening programs. Understanding what factors (e.g., knowledge, attitudes) will impact on HPV test acceptability by women is crucial for ensuring adequate public health practices to optimize cervical screening uptake. We used mixed methods research synthesis to provide a categorization of the relevant factors related to HPV primary screening for cervical cancer and describe their influence on womens acceptability of HPV testing. We searched Medline, Embase, PsycINFO, CINAHL, Global Health and Web of Science for journal articles between January 1, 1980 and October 31, 2017 and retained 22 empirical articles. Our results show that while most factors associated with HPV test acceptability are included in the Health Belief Model and/or Theory of Planned Behavior (e.g., attitudes, knowledge), other important factors are not encompassed by these theoretical frameworks (e.g., health behaviors, negative emotional reactions related to HPV testing). The direction of influence of psychosocial factors on HPV test acceptability was synthesized based on 14 quantitative studies as: facilitators (e.g., high perceived HPV test benefits), barriers (e.g., negative attitudes towards increased screening intervals), contradictory evidence (e.g., sexual history) and no impact (e.g., high perceived severity of HPV infection). Further population-based studies are needed to confirm the impact of these factors on HPV-based screening acceptability.
BMC Public Health | 2016
Samara Perez; Ovidiu Tatar; Gilla K. Shapiro; Eve Dubé; Gina Ogilvie; Juliet Guichon; Vladimir Gilca; Zeev Rosberger
Preventive Medicine | 2016
Samara Perez; Ovidiu Tatar; Remo Ostini; Gilla K. Shapiro; Jo Waller; Gregory D. Zimet; Zeev Rosberger
Sexually Transmitted Diseases | 2016
Samara Perez; Gilla K. Shapiro; Ovidiu Tatar; Keven Joyal-Desmarais; Zeev Rosberger
Vaccine | 2017
Samara Perez; Ovidiu Tatar; Vladimir Gilca; Gilla K. Shapiro; Gina Ogilvie; Juliet Guichon; Anila Naz; Zeev Rosberger
Vaccine | 2018
Gilla K. Shapiro; Ovidiu Tatar; Eve Dubé; Rhonda Amsel; Bärbel Knäuper; Anila Naz; Samara Perez; Zeev Rosberger
Papillomavirus Research | 2017
Ovidiu Tatar; Samara Perez; Anila Naz; Gilla K. Shapiro; Zeev Rosberger
International Journal of Clinical Pharmacy | 2017
Edeltraut Kröger; Ovidiu Tatar; Isabelle Vedel; Anik Giguère; Philippe Voyer; Laurence Guillaumie; Jean-Pierre Grégoire; Line Guénette
Preventive Medicine | 2018
Gilla K. Shapiro; Ovidiu Tatar; Rhonda Amsel; Gillian Prue; Gregory D. Zimet; Bärbel Knäuper; Zeev Rosberger